Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RORγt is an isoform of RORγ, a member of the nuclear receptor superfamily. It is a master regulator of Th17 cell differentiation and IL-17 production, playing a critical role in immune responses. Dysregulation of RORγt contributes to autoimmune diseases, making it a therapeutic target for conditions like rheumatoid arthritis, multiple sclerosis, and psoriasis. Small molecule inhibitors targeting RORγt are under development.
Small molecule inhibitors targeting orthosteric or allosteric sites of RORγt to suppress Th17-mediated inflammation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Retinoic acid receptor-related orphan nuclear receptor gamma truncated (RORγt).